Metastasis represents an end stage in the evolution of cancer progression and has been related to specific genetic pathways. Overexpression of mutant RAS in particular appears to promote invasion and metastasis, although exactly how this occurs has not been well characterized. It was previously showed that activation of the WASF3 protein regulates actin cytoskeleton dynamics that promote invasion. In this report, how WASF3 overexpression interacts with mutant RAS to increase invasion and metastasis was investigated. The ability of RAS to promote invasion and metastasis was shown to be dependent on WASF3 activation in a PI3K and AKT dependent manner. Proteomics analysis demonstrates the presence of AKT in the WASF3 immunocomplex which is enhanced by overexpression of mutant RAS. During these processes activation of ERK1/2 is not 
| I N T R O D U C T I O N
The RAS genes are among the most commonly mutated oncogenes in human cancers particularly in certain types such as colon, pancreas and lung. 1 In addition to mutational activation, RAS genes are also often overexpressed in cancers such as breast and pancreas. In normal cells, growth factor stimulation leads to the activation of the RAS genes through switches between their GDP-bound inactive and GTP-bound active form, which promotes a variety of cellular responses. Normally this GDP-GTP transition is under tight regulation, but in cancer cells mutations in the RAS genes, largely at codons 12, 13, and 61, lead to constitutive activation of RAS by stabilizing the GTP-bound form. 2 One of the main consequences of RAS activation is the promotion of invasion and metastasis, although the underlying mechanism is poorly understood. 2 RAS activation leads to stimulation of the MAPK/ERK pathway leading to increased cell proliferation 3, 4 as well as the PI3 kinase (PI3K) pathway, which elicits a variety of cellular responses including invasion and metastasis. 5 While the promotion of invasion and metastasis is a complex genetic process, 6 there are master proteins such as WASF3, which promote metastasis when overexpressed and, when inactivated, lead to suppression of invasion and metastasis, even in cells that overexpress mutant RAS. 7, 8 WASF3 is a member of the Wiskott-Aldridge family of proteins 9 whose primary function is to regulate actin cytoskeleton dynamics leading to stimulation of membrane protrusion that lead to cell movement and invasion. 10 Knockdown of WASF3 in a variety of different cancer cell types leads to suppression of lamellipodia formation leading to suppression of invasion in vitro 11, 12 and metastasis in vivo. 8, 12 WASF3 also influences a series of pathways and genes that are related to metastasis [11] [12] [13] and its over expression is correlated with increased aggression and poor survival in primary breast cancers. 14 
| In vivo metastasis assays
All experimental procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) of Augusta University. Six-week-old SCID mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were injected with 1 3 10 6 cells via lateral tail veins to establish tumor metastasis models as described previously. 8 The mice
were sacrificed on day 56 and metastatic nodules on the surface of the lung and liver were counted. The lungs and livers were then fixed and processed for histological analyses. Hematoxylin and eosin (H&E) staining was used to examine tumor metastasis in the lung and liver.
| R E S U L T S 3.1 | Mutant KRAS enhances WASFphosphoactivation and invasion in MCF10A cells
To address fundamental relationships between WASF3 and RAS, we first used a normal cell system that expresses both genes at endoge- , they become invasive in vitro. 21 Many cancer cells, however, express mutant RAS at physiologically normally regulated levels. 22 To investigate how WASF3 is affected under these circumstances, we used the isogenic pairs of MCF10A cells described by
Ref. 20 , which have been engineered to express endogenously either KRAS G12V or KRAS WT monoallelically. WASF3 protein levels in these isogenic pairs were identical ( Figure 1B ). In contrast, forced overexpression of KRAS G12V in MCF10A cells, while not altering WASF3 protein levels ( Figure 1B ), dramatically increased WASF3 phosphorylation levels ( Figure 1C ).
While knockdown of WASF3 in aggressive breast cancer cells leads to loss of invasion, 7 knockdown of WASF3 in MCF10A cells ( Figure   1D ) did not affect endogenous invasion levels ( Figure 1E ). In contrast, when WASF3 was knocked down in MCF10A cells overexpressing (Figure 2A ). In contrast, only a small change in pAKT levels was observed when WASF3 was knocked down in the cells expressing KRAS G12V at endogenous levels ( Figure   2A ). pAKT levels in MCF10A were comparable between cells expressing either KRAS WT or KRAS
G12V
, but higher in cells overexpressing KRAS G12V ( Figure 2B ). Analysis of WASF3 phosphorylation levels in these MCF10A cells showed dramatically higher levels in cells overexpressing KRAS G12V compared with those expressing monoallelic KRAS WT or KRAS G12V ( Figure 2B ). These data indicate that high-level expression of mutant KRAS enhances WASF3 activation, and activated WASF3 may participate in facilitating AKT phosphoactivation.
To extend these observations to metastatic tumor cells, we investigated the relationship between WASF3 and RAS expression in MDA-MB-231 breast cancer cells which express KRAS
. In our previous studies of WASF3-associated proteins in MDA-MB-231 cells using mass spectrometry analysis, 13, 23 we identified the AKT Interacting Protein (AKTIP) in the WASF3 immunocomplex, supporting the possibility that WASF3 interacts with AKT (Supporting Information Figure S1 ). To confirm this interaction, we performed IP from MDA-MB-231 cells and Figure 2C ). The p85 regulatory component of PI3K was also present ( Figure 2C ), as we have described previously. 11 When WASF3 was knocked down in MDA-MB-231 cells, levels of activated pAKT were suppressed ( Figure 2D ), suggesting a functional interaction between WASF3 and AKT. In contrast, when WASF3 was knocked down in SKBR3 cells, which harbor wild type KRAS, pAKT levels were not affected ( Figure 2D ). When KRAS G12V was overexpressed in parental T47D breast cancer cells, which do not normally express WASF3 16 and also harbor a wild-type KRAS gene, pAKT levels increased ( Figure 2E) and when WASF3 was also overexpressed in these cells ( Figure 2E) pAKT levels were further increased. These studies establish that the ability of mutant RAS to mediate activation of AKT is dependent on WASF3.
3.3 | Knockdown of WASF3 leads to reduced pAKT levels, invasion, and metastasis in colon cancer cells
We next extended our studies relating RAS and WASF3 expression from non-transformed cells to cancer cells. Although KRAS mutations are seen in many different cancers, they are particularly prevalent in colon cancers, 1 and have been shown to play a critical role in the oncogenic progression of colon cancer. 2 We, therefore, investigated the relationship between WASF3 and KRAS in colon cancer cell lines. Here, the positive relationship between WASF3 expression levels and invasion is maintained ( Figure 3A) . Non-invasive SW48 cells express
KRAS WT
, poorly invasive HCT116 cells express KRAS G12V at low levels and metastatic SW620 cells express KRAS G12V at high levels. 21 When WASF3 was knocked down in these three colon cancer cell lines, there was a proportional reduction in both pAKT levels ( Figure 3A ) and invasion ( Figure 3B ) in HCT116 and SW620 cells, but not in SW48 cells.
Thus, as in the breast cell systems described above, WASF3 expression is also associated with AKT phosphorylation in the presence of mutant 
| WASF3 activation influences the interaction between p85 and p110
The catalytic activity of the p110 subunit of PI3K, which activates AKT, is suppressed through association with the p85 subunit. Immunoprecipitation of WASF3 from MDA-MB-231 cells shows the presence of p85 and AKT in the immunocomplex (C). When WASF3 was knocked down in MDA-MB-231 cells, phospho-AKT levels were reduced whereas there was no effect on pAKT when WASF3 was knocked down in SKBR3 cells (D). Overexpression of mutant KRAS (G12V) in T47D cells leads to increased pAKT levels which was more significant when WASF3 was also overexpressed (D). Overexpression of mutant KRAS (G12V) in T47D cells leads to increased pAKT levels which was more significant when WASF3 was also overexpressed (E) the endogenous p85 protein was immunoprecipitated from MCF10A isogenic pairs, higher levels of WASF3 protein were seen in the p85
immunocomplex from cells expressing KRAS G12V compared with the cells expressing KRAS WT ( Figure 5A ). Together with the results shown in Figure 2B , these observations suggest that this association depends on WASF3 phosphorylation. We have previously shown that overexpression of WASF3 in the non-metastatic T47D breast cancer cells increases motility. 16 When KRAS G12V was introduced into T47D cells overexpressing exogenous WASF3, there was a reduction in the levels of p110 associated with p85, supporting increased PI3K activity ( Figure   5B ). In contrast, knockdown of WASF3 in either breast cancer MDA-MB-231 cells ( Figure 5C ) or colon cancer SW620 cells ( Figure   5D ), led to an enhanced interaction between p85 and p110. It appears, therefore, that WASF3 influences increased dissociation between p85 and p110, accounting for increased AKT activation ( Figure 5E ).
| WASF3 is an important mediator in KRAS-AKT signaling
When KRAS G12V was overexpressed in HCT116 cells showing monoallelic expression of KRAS WT , both pWASF3 and pAKT levels were increased ( Figure 6A ). When mutant KRAS was knocked down in the FIG URE 3 Expression levels of WASF3 are increased in highly invasive SW620 cells compared with less invasive HCT116 and noninvasive SW48 cells (A). pAKT levels are also reduced proportional to the endogenous levels of WASF3 expression. Knockdown of WASF3 in these three cell lines shows no effect on invasion for SW48 cells, a significant suppression of invasion in HCT116 cells and a highly significant suppression of invasion in SW620 cells (B). Metastasis assays for SW620 cells in SCID mice shows a reduced number of surface nodules on the livers from cells in which WASF3 was knocked down (C), which was also seen in the lungs from the same animals (D). 
| DISCUSSION
The association between mutant RAS and increased invasion and met- Although there is evidence that mutated RAS can promote invasion, this effect is more pronounced when it is also overexpressed as seen in the MCF10A model presented here. Furthermore, although isolated studies suggest a wild type allele has a neutral or positive effect on the malignant phenotype, the majority of studies suggest a wild type allele has a suppressive effect over a mutant allele when expressed at physiologically regulated levels. 22 Our studies using isogenic HCT 116 cancer cells show this suppressive effect on invasion in cells heterozygous for mutant RAS but loss of the WT allele in these cells enhances the effect of the mutant allele on invasion in a WASF3-dependent manner. This is the proposed underlying basis for loss of heterozygosity at the RAS loci which eliminates the wild type allele. 23 Since the levels of activated WASF3 seem to be proportional to the invasion potential in cancer cells it is consistent that higher levels of mutant RAS leads to increased WASF3 activation not seen when RAS is expressed at physiological levels. This is supported by the activation of AKT which is again not increased in the isogenic pairs described by Ref. 20 but is increased when RAS is overexpressed and is lost when WASF3 is knocked down. These studies, therefore, provide an explanation for the role of mutant RAS in promoting invasion and metastasis which involve activation of signaling pathways in a WASF3-dependent manner.
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